Global Sustained Release Excipients Market

Sustained Release Excipients Market Size, Share, Growth Analysis, By Product type(Gelatin, Polymers), By Route of Administration(Oral, Intramuscular), By Technology(Targeted Delivery, Microencapsulation) - Industry Forecast 2024-2031

Report ID: SQMIG35I2231 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 96 | Figures: 76

Share your requirements to help us to customize the report.
   I acknowledge that I have read the Privacy Policy
Confidentiality

We respect your privacy rights and safeguard your personal information. We prevent the disclosure of personal information to third parties.

Analyst Support
$5,300
BUY NOW GET FREE SAMPLE

FAQs

Sustained Release Excipients Market size was valued at USD 1.26 billion in 2022 and is poised to grow from USD 1.37 billion in 2023 to USD 2.60 billion by 2031, growing at a CAGR of 8.4% in the forecast period (2024-2031).

The competitive landscape in the market is defined by the several companies engaged in fierce competition to gain a competitive advantage by focusing on R&D to develop new excipient formulations and delivery systems. Market players are employing strategic partnerships and acquisitions to expand their reach. 'Allergan PLC (Ireland)', 'AstraZeneca (UK)', 'GlaxoSmithKline PLC (UK)', 'Mayne Pharma Group Limited (Australia)', 'Mylan NV (US)', 'Novartis AG (Switzerland)', 'Pfizer Inc. (US)', 'Salix Pharmaceuticals (US)', 'Sun Pharmaceutical Industries Ltd (India)', 'Roche Holdings AG (Switzerland)', 'Sanofi (France)', 'Johnson & Johnson (US)', 'Eli Lilly and Company (US)', 'Merck & Co., Inc. (US)', 'Teva Pharmaceutical Industries Ltd (Israel)', 'AbbVie Inc. (US)', 'Bristol-Myers Squibb (US)', 'Gilead Sciences, Inc. (US)', 'Bayer AG (Germany)', 'Takeda Pharmaceutical Company Limited (Japan)'

The constantly aging population is driving this market as the demographic landscape shifts to an older age population, propelling demand for healthcare products and pharmaceuticals. Sustained release excipients provide benefits like extended drug release to improve compliance and manage chronic conditions effectively, cementing its importance producing medications that cater to the specific needs of elderly patients. As healthcare providers target the healthcare challenges associated with an aging population, this demographic shift will drive steady demand for sustained release excipients in the pharmaceutical sector.

Increased Focus on Personalized Medicine : The growing emphasis on personalized medicine is trending in the pharmaceutical industry, including the sustained release excipients market. Advances in biomarker identification and genomics are targeting the development of medications designed according to individual patient profiles. Sustained excipients enable precise dosing and prompt timing of optimized release in therapeutic outcomes while minimizing side effects, highlighting its significance in formulation of these personalized drug delivery systems. This trend is in line with the shift towards patient-centric healthcare, driving innovation in excipient formulations and technologies.

North America dominates the market due to its thriving pharmaceutical industry, enriched by rigorous R&D, making it a centre for drug formulation. The adoption of sustained release excipients is being driven further by a strong emphasis on patient-centric healthcare and rigid regulatory standards placed to guarantee drug efficiency and safety. The region’s position in the market is strengthened by its substantial healthcare expenditure and large presence of renowned pharmaceutical companies.

Related Reports

Epinephrine Market
Buy Now GET FREE SAMPLE
Vitamin K2 Market
Buy Now GET FREE SAMPLE
Atopic Dermatitis Drugs Market
Buy Now GET FREE SAMPLE
Cancer Vaccines Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Sustained Release Excipients Market

Product ID: SQMIG35I2231

$5,300
BUY NOW GET FREE SAMPLE